

# Hepatitis C - Pipeline Review, H2 2020

<https://marketpublishers.com/r/HE5876B7CC2EN.html>

Date: September 2020

Pages: 426

Price: US\$ 2,000.00 (Single User License)

ID: HE5876B7CC2EN

## Abstracts

Hepatitis C - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2020, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 9, 15, 2, 32, 24 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 13 and 18 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Hepatitis C - Overview
- Hepatitis C - Therapeutics Development
- Hepatitis C - Therapeutics Assessment
- Hepatitis C - Companies Involved in Therapeutics Development
- Hepatitis C - Drug Profiles
- Hepatitis C - Dormant Projects
- Hepatitis C - Discontinued Products
- Hepatitis C - Product Development Milestones
- Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hepatitis C, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Hepatitis C - Pipeline by AB Pharma Ltd, H2 2020  
Hepatitis C - Pipeline by AbbVie Inc, H2 2020  
Hepatitis C - Pipeline by Akshaya Bio Inc, H2 2020  
Hepatitis C - Pipeline by Alla Chem LLC, H2 2020  
Hepatitis C - Pipeline by Ascletis Pharma Inc, H2 2020  
Hepatitis C - Pipeline by Atea Pharmaceuticals Inc, H2 2020  
Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2020  
Hepatitis C - Pipeline by Beta Pharma Inc, H2 2020  
Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H2 2020  
Hepatitis C - Pipeline by Biotron Ltd, H2 2020  
Hepatitis C - Dormant Projects, H2 2020  
Hepatitis C - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hepatitis C, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

AB Pharma Ltd  
AbbVie Inc  
Akshaya Bio Inc  
Alla Chem LLC  
Ascletis Pharma Inc  
Atea Pharmaceuticals Inc  
Beijing Kawin Technology Share-Holding Co Ltd  
Beta Pharma Inc  
Biotest Pharmaceuticals Corp  
Biotron Ltd  
Bolder Biotechnology Inc  
Chia Tai Tianqing Pharmaceutical Group Co Ltd  
Cocrystal Pharma Inc  
Combioxin SA  
Cytocom Inc  
DEKK-TEC Inc  
Dongguan HEC TaiGen Biopharmaceuticals Co Ltd  
Ena Therapeutics Pty Ltd  
Ennaid Therapeutics LLC  
F. Hoffmann-La Roche Ltd  
FortuneRock (China) Ltd

Galactica Biotech Ltd  
GeneCure LLC  
Genoscience Pharma  
Gilead Sciences Inc  
Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd  
GlaxoSmithKline Plc  
HEC Pharm Co Ltd  
Hepion Pharmaceuticals Inc  
ImmunoBiology Ltd  
Immunotope Inc  
Inovio Pharmaceuticals Inc  
Integrated BioTherapeutics Inc  
iQur Ltd  
J2H Biotech  
Medivir AB  
Merck & Co Inc  
MetalloPharm LLC  
Microbio Co Ltd  
Nanjing Sanhome Pharmaceutical Co Ltd  
Nanogen Biopharmaceutical Co  
Novalex Therapeutics Inc  
Ono Pharmaceutical Co Ltd  
Orgenesis Inc  
Palisades Therapeutics  
PharmaEssentia Corp  
Presidio Pharmaceuticals Inc  
Profectus BioSciences Inc  
Regulus Therapeutics Inc  
Riboscience LLC  
Rodas BioTarget GmbH  
Savoy Pharmaceuticals Inc  
Shanghai Newsummit Biopharma Co Ltd  
Shanghai Tangrun Pharmaceuticals Co Ltd  
Sino Biopharmaceutical Ltd  
Sudershan Biotech Ltd  
TaiGen Biotechnology Co Ltd  
Tetranov International Inc  
TGV Laboratories Inc  
Therapure Biopharma Inc

THEVAX Genetics Vaccine USA Inc  
Toray Industries Inc  
Trek Therapeutics PBC  
UBI Pharma Inc  
Vanworld Pharmaceutical (Rugao) Company Ltd  
Vertex Pharmaceuticals Inc  
Virocovax  
Zylacta Corp



## I would like to order

Product name: Hepatitis C - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/HE5876B7CC2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE5876B7CC2EN.html>